Anglia Ruskin University Featured PhD Programmes
University of Glasgow Featured PhD Programmes
University of Kent Featured PhD Programmes
National University of Ireland, Galway Featured PhD Programmes
University of Exeter Featured PhD Programmes
"t" AND "cell"×
10 miles

Cancer / Oncology (t cell) PhD Projects, Programs & Scholarships

We have 34 Cancer / Oncology (t cell) PhD Projects, Programs & Scholarships

  • "t" AND "cell" ×
  • Cancer / Oncology×
  • clear all
Order by 
Showing 1 to 10 of 34
  Identification of key determinants affecting the quality of human Cancer specific cytotoxic T cells
  Prof T Dong
Application Deadline: 24 July 2020

Funding Type

PhD Type

The main objective of my group’s research is to focus on the functional aspects of the antigen specific T cells and study the factors affecting Cytotoxic T cells in controlling cancer development.
  Identification of key determinants affecting the quality of human Cancer specific cytotoxic T cells
  Prof T Dong
Application Deadline: 24 July 2020

Funding Type

PhD Type

The main objective of my group’s research is to focus on the functional aspects of the antigen specific T cells and study the factors affecting Cytotoxic T cells in controlling cancer development.
  Metabolic control of T cell function
  Dr S Dimeloe
Applications accepted all year round

Funding Type

PhD Type

Current research interests in Sarah Dimeloe’s lab focus on the metabolism and interlinked immune function of T lymphocytes in health and disease.
  Egr2 and 3 mediated T cell tolerance in cancer and their impact in immune checkpoint therapy
  Dr S Li
Applications accepted all year round

Funding Type

PhD Type

Tumour infiltrated lymphocytes (TILs) contain tumour reactive T cells and have been used as adoptive cell transfer therapy in patients which can mediate cancer regression.
  Exploring The Therapeutic Window of CAR-T Cell Therapy
  Dr M Chapman, Dr J Thaventhiran
Application Deadline: 10 February 2020

Funding Type

PhD Type

Immunotherapy, including chimeric antigen receptor-T cells (CAR-T cells) and checkpoint inhibition, is a powerful new class of cancer treatment.
  A multiple modality approach for targeting treatment-resistant ovarian cancer
  Dr E. Sanij, Prof R. Pearson
Applications accepted all year round

Funding Type

PhD Type

High-grade serous ovarian cancer (HGSOC) accounts for 70% of ovarian cancer (OvCa) deaths and its five-year survival rate is 43%.
  Using T cells to eradicate cancer
  Prof T. Tiganis
Applications accepted all year round

Funding Type

PhD Type

The Tiganis Laboratory is seeking a highly enthusiastic student to conduct research in immuno-oncology and the development of novel immunotherapeutic approaches for the treatment of cancer.
  Exploiting tumour-promoting paracrine signals in solid cancers to turbocharge genetically redirected T cells
  Dr A Hurlstone, Prof R Edmondson
Applications accepted all year round

Funding Type

PhD Type

Adoptive cell therapy (ACT) using tumour infiltrating lymphocytes (TILs) or genetically redirected T cells are some of the most promising approaches to emerge recently for the treatment of metastatic disease.
  Regulation of host cell DNA damage response pathways by adenovirus
  Dr A S Turnell, Dr C McCabe
Applications accepted all year round

Funding Type

PhD Type

Human adenoviruses are small non-enveloped viruses with a linear, double-stranded DNA genome. Adenovirus has long served as a faithful model for dissecting the molecular basis of key cellular signalling pathways that regulate fundamental biological processes such as cell growth, cell differentiation and cell death.
  (MCRC Non-Clinical) The COX-2 associated inflammatory pathway as a potential biomarker for early detection in lung cancer
  Prof C Dive, Dr S Zelenay, Dr Elaine Kilgour, Dr P Crosbie
Application Deadline: 26 January 2020

Funding Type

PhD Type

Lung Cancer is the leading cause of cancer-related mortality world-wide and of pre-mature death in Manchester. Non-small cell lung cancer patients whose disease is detected sufficiently early (Stage I-IIIA) undergo surgery with curative intent, however about 40% subsequently relapse with metastatic disease.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2020
All rights reserved.